Merck's vicriviroc, also a CCR5 antagonist, a class that has little role in HIV treatment, failed in two phase III studies in experienced HIV patients.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.